NRx Pharmaceuticals has performed its clinical study in critical COVID-19 patients [ 63 ], finding good safety data, significative improvements in the levels of oxygenation and pulmonary function since the first days of treatment and a highly significant four-fold increased probability of survival.
← all excerpts
Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective.
1
—
—